Details for New Drug Application (NDA): 017669
✉ Email this page to a colleague
NDA 017669 describes TENUATE, which is a drug marketed by Sanofi Aventis Us and Nostrum Labs Inc and is included in four NDAs. Additional details are available on the TENUATE profile page.
The generic ingredient in TENUATE is diethylpropion hydrochloride. There are eleven drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the diethylpropion hydrochloride profile page.
The generic ingredient in TENUATE is diethylpropion hydrochloride. There are eleven drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the diethylpropion hydrochloride profile page.
Summary for 017669
| Tradename: | TENUATE |
| Applicant: | Sanofi Aventis Us |
| Ingredient: | diethylpropion hydrochloride |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 017669
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 75MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
